Recruiting

Comprehensive Clinical Evaluation Study of GLP-1RA

Lead sponsor

LI YAN

Assets

Liraglutide / Semaglutide

Listed sites

Recruiting sites

Estimated enrollment

492

Study population

Type 2 diabetes

Eligibility highlights

Primary endpoints

•HbA1c <7.0% achievement•Weight reduction

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06686134

Org study IDQFS-LY-2024-GLP-1RA-001

Timeline

Milestones

Study start2024-07-01actual

Study first posted2024-11-13actual

Last update posted2024-11-13actual

Primary completion2025-12-31estimated

Study completion2026-07-31estimated

Assets

Investigational agents

Liraglutide Semaglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

type 2 diabetes

Inclusion criteria

•Diagnosed with type 2 diabetes;

•no study drug has been used in the last three months;

•Existing hypoglycemic programs include investigational drugs;

•Age ≥18 years old;

•The patient's demographic data, disease history, course records, laboratory test indicators, drug use and other information were complete;

•Sign informed consent.

Exclusion criteria

•persistent influenza, autoimmune disease, or other metabolic disease;

•There are obvious gastrointestinal diseases, gastrointestinal resection or malabsorption syndrome;

•diet drugs, glucocorticoids, drugs affecting gastrointestinal motility are being used;

•Patients with severe liver and kidney function impairment and patients with malignant tumors;

•Pregnant or lactating women.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Weight & body composition

1 endpoint

Primary/protocol endpoint

Weight reduction from baseline

Time frame:4, 8, 12, and 16 weeks after the start of medication

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

HbA1c compliance rate

Time frame:4, 8, 12, and 16 weeks after the start of medication

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
The lancet. Diabetes & endocrinology2018 Apr (month)PMID29397376doi:10.1016/S2213-8587(18)30024-Xvia CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.